Novo Nordisk A/S: Mim8 showed better reductions in annual bleeding rates (ABR) than on-demand treatments and previous prophylaxis in haemophilia A patients.

The U.S. Food and Drug Administration (FDA) approved Eptinezumab on February 21, 2020.

In pre-clinical models, DA-1726 from NeuroBo Pharmaceuticals outperformed Survodutide in weight reduction, maintaining lean body mass, and lowering lipid levels.

The U.S. Food and Drug Administration (FDA) approved Palforzia on January 31, 2020.

Sun Pharma's GL0034 (Utreglutide) Showcases Remarkable Weight Loss and Metabolic Improvements in Obesity at ADA's 84th Session.

The U.S. Food and Drug Administration (FDA) approved Trijardy XR on January 27, 2020, for the treatment of type 2 diabetes in adults.

Takeda Reveals New Data from Phase 2b Study of Mezagitamab, Showing Potential to Innovate Primary Immune Thrombocytopenia Treatment.

The U.S. Food and Drug Administration (FDA) approved Tazemetostat on January 23, 2020, for the treatment of specific types of advanced cancers, specifically epithelioid sarcoma and follicular lymphoma.

Bristol Myers Squibb's application for subcutaneous nivolumab has been validated by the European Medicines Agency.

The U.S. Food and Drug Administration (FDA) approved Teprotumumab on January 21, 2020, for the treatment of Thyroid Eye Disease (TED), also known as Graves' Eye Disease.

argenx Reveals FDA Nod for VYVGART Hytrulo in Treating Chronic Inflammatory Demyelinating Polyneuropathy.

The U.S. Food and Drug Administration (FDA) approved Avapritinib on January 9, 2020, for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.